midazolam and pf-00562271

midazolam has been researched along with pf-00562271 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burris, HA; Camidge, DR; Chen, EX; Fingert, H; Hicks, RJ; Infante, JR; Mileshkin, LR; Pierce, KJ; Rischin, D; Roberts, WG; Shreeve, SM; Siu, LL; Xu, H	1

Trials

1 trial(s) available for midazolam and pf-00562271

Article	Year
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-01, Volume: 30, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Canada; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Nonlinear Dynamics; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Radiopharmaceuticals; Sulfonamides; Treatment Outcome; United States	2012

Article

Year

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-01, Volume: 30, Issue:13

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Canada; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Nonlinear Dynamics; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Radiopharmaceuticals; Sulfonamides; Treatment Outcome; United States

2012